Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia

Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at lea...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Leukemia
Main Authors: Cross, N C P, White, H E, Colomer, D, Ehrencrona, H, Foroni, L, Gottardi, E, Lange, T, Lion, T, Machova Polakova, K, Dulucq, S, Martinelli, G, Oppliger Leibundgut, E, Pallisgaard, N, Barbany, G, Sacha, T, Talmaci, R, Izzo, B, Saglio, G, Pane, F, Müller, M C, Hochhaus, A
פורמט: Artigo
שפה:Inglês
יצא לאור: Nature Publishing Group 2015
נושאים:
Review
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4430701/
https://ncbi.nlm.nih.gov/pubmed/25652737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2015.29
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים